IVF Outcome Following Progestogen Ovarian Stimulation
Status:
Completed
Trial end date:
2019-05-09
Target enrollment:
Participant gender:
Summary
The new strategy is by using the progestogen to block the luteinizing hormone(LH) surge
either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e
progestin primed ovarian stimulation (PPOS). The goal of PPOS is to develop a single dominant
follicle. Various types of oral Progestin had been studied before including
Medroxyprogesterone Acetate (MPA) and Utrogestan with different dosage. A different study by
Wang et al conducted by using MPA to patients with PCOS. The use of MPA is contraindicated in
human pregnancy whereas Dydrogesterone had been extensively used worldwide for the treatment
of threatened miscarriage as well as luteal support in infertility setting. Previous protocol
on PPOS showed inconclusive results. Therefore in this study, Dydrogesterone was used as the
Progestin Primed Ovarian hyperstimulation to explore its effect on PCOS women IVF outcome.